Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Merck Introduces New Single-use Technologies to Advance Flexible Manufacturing

Merck
Posted on: 17 Apr 18
  • Innovations include first-of-its-kind single-use tangential flow filtration capsule for bioprocessing of antibody-drug conjugates and monoclonal antibodies
  • Tangential flow filtration capsule, final fill capsule filter and large-scale mixers designed with operators in mind
  • New products reduce risk, improve speed and ease of use

 

 

Darmstadt, Germany, April 17, 2018 – Merck, a leading science and technology company, today introduced three new products to support flexible manufacturing of biologics. The innovations, all designed to make single-use bioprocessing easier, safer and more efficient, will be unveiled at the International Pharmaceutical Expo (INTERPHEX), New York City, USA.

 

They are:

 

“The biopharmaceutical industry needs flexible manufacturing solutions that reduce long drug development timelines and accommodate shifts in demand, while protecting employees and the environment,” said Andrew Bulpin, head of the Process Solutions business unit, Life Science, at Merck. “Merck’s new bioprocessing innovations demonstrate our commitment to developing superior single-use technologies that will drive implementation of flexible manufacturing technologies around the world.”

 

At INTERPHEX -- the premier pharmaceutical, biotechnology and medical device development and manufacturing event in the U.S. -- Merck introduced its Pellicon® Capsule with Ultracel® Membrane is the first-of-its-kind single-use tangential flow filtration capsule for bioprocessing of antibody-drug conjugates and monoclonal antibodies. The capsule combines fast, user-friendly and efficient processing of biologics with reliable performance and linear scalability. The capsule also reduces risk of product cross-contamination as well as exposure to highly toxic compounds during processing and disassembly. It is the newest addition to Merck’s industry-leading Pellicon® ultrafiltration product family.

 

Also introduced at INTERPHEX is Merck’s Millipak® Final Fill Filter. This filter was designed with an angled, innovative aseptic Multi-Purpose Port for sampling, venting and integrity testing through the same port while protecting against microbial contamination and ensuring sterility of the drug product. The stacked disc design maximizes product yield and the transparent housing clearly shows fluid flow during the critical final filtration step.

 

Merck’s new Mobius® Power MIX 2,500-Litre and 3,000-Litre single-use mixers handle difficult-to-mix buffers, cell culture media powders and other pharmaceutical ingredients. Both large-scale systems incorporate NovAseptic® technology, traditionally used in stainless steel mixers, saving time and enabling more efficient single-use mixing. The new mixers extend Merck’s product line, which now includes single-use mixing at scales ranging from 100 litres to 3,000 litres. All Mobius® Power MIX systems offer easy bag installation and product sampling to save customers’ time.

 

Merck representatives will be available to discuss these innovative technologies at Booth 2841 at INTERPHEX, April 17–19, at the Javits Center in New York City, USA.

 

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

 

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. More than 52,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of €15.3 billion in 66 countries.

 

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

 

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 17/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.